Tools and resources
ASCO living guideline on Treatment of multiple myeloma
ASCO’s living guideline covers treatment across the myeloma pathway. This update focuses on relapsed or refractory myeloma, recommending ciltacabtagene autoleucel and teclistamab plus daratumumab as preferred options at first relapse for eligible patients who have not previously received BCMA-directed treatment.
ASCO GuidelineBSH guideline on Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics
Read the British Society for Haematology guideline on early diagnosis of AL amyloidosis, including when to suspect it and when urgent haematology review may be needed.
BSH GuidelineBSH/UKMS guideline on Management of relapsed multiple myeloma
This British Society of Haematology and UK Myeloma Society guideline on the management of relapsed and refractory myeloma was developed to support clinicians making treatment decisions after disease progression following at least one prior line of treatment.
UKMRA Frailty Group guideline on Assessment and treatment of frail patients living with multiple myeloma
The UK Myeloma Research Alliance Frailty Group has published a new guideline on assessing and treating frailty in people with myeloma.
Other GuidelineIMS and IMWG consensus recommendations on the Definition of High-Risk Multiple Myeloma
The International Myeloma Society and International Myeloma Working Group have published updated consensus recommendations on the definition of high-risk myeloma.
BSH good practice paper on Diagnosis and management of monoclonal gammopathy of renal significance
The paper outlines a consensus approach to diagnosis, treatment and monitoring of MGRS, including guidance on the investigations required to confirm the condition, principles of supportive care, and haematological treatment strategies. It also highlights the need for ongoing multidisciplinary collaboration in managing this rare but clinically important disorder.
BSH GuidelineBSH/UKMS good practice paper on Advanced imaging for earlier diagnosis and morbidity prevention in myeloma
This Good Practice Paper from BSH/UKMS provides expert recommendations on the use of advanced imaging techniques, such as whole-body MRI and FDG-PET/CT, in the diagnosis and management of myeloma. It emphasises the importance of early detection of bone marrow disease to prevent complications and improve patient outcomes.
IMWG consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma
CAR T-cell therapy offers new treatment possibilities for advanced myeloma with high response rates. This expert-backed guidance supports clinicians in managing its unique effects safely and effectively.
IMWG GuidelineBSH/UKMS good practice paper on Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients
The British Society for Haematology (BSH) and UK Myeloma Society (UKMS) have published a Good Practice Paper offering recommendations on the diagnosis and early treatment of transplant-eligible patients with high-risk myeloma.
IMWG immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Step into the forefront of myeloma treatment with this latest publication from the International Myeloma Working Group immunotherapy committee.
IMWG Guideline
- 1